ADULT AIDS CLINICAL TRIALS UNIT

成人艾滋病临床试验单位

• 批准号: 7578382
• 负责人: MITCHELL GOLDMAN
• 金额: $ 45.26万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-01-01 至 2008-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7578382
• 关键词: AIDS clinical trial group; Adult; African American; Anti-Retroviral Agents; Anus; Apoptosis; Biological Availability; Cells; Clinical Trials; Community Hospitals; Conduct Clinical Trials; Dementia; Drug Interactions; Dysplasia; Evolution; Failure; Granulocyte-Macrophage Colony-Stimulating Factor; HIV; HIV-1; Highly Active Antiretroviral Therapy; Hospitals; Human Papillomavirus; Immunity; Immunology; Indiana; Intestines; Laboratories; Ligands; Metabolism; Minority; Neurologic; Pathogenesis; Patients; Pharmaceutical Preparations; Pharmacology; Positioning Attribute; Protease Inhibitor; Protocols documentation; Research Infrastructure; Research Personnel; Role; Salvage Therapy; Site; Universities; Woman; Work; base; concept; cost; cost efficient; efavirenz; gp-120 Antigen; in vitro Assay; member; virology

The Indiana University proposes to build upon the following in the renewal application: (1) scientific and administrative contributions. The Indiana ACTU ranks among the top 20 percent of ACTUs scientifically; (2) cost efficient accrual into AACTG trials. Indiana ranked third in cost weighed accrual; and (3) recruitment of women and minorities. The ACTU ranked second in recruitment of African- Americans and third in women. The long-term objectives of this site are to: expand scientific and administrative contributions through recruitment of additional investigators; increase accrual potential for women and minorities by expansion of the Wishard Hospital subunit; and increase the patient base by establishing a subunit at Community Hospital of Indianapolis. The first specific aim of the Indiana University ACTU is to contribute scientifically through submission of concept proposals and memberships on AACTG protocol teams and committees. Currently, Indiana investigators hold 32 positions on protocol teams. Concepts are proposed for: (a) salvage therapy for efavirenz failures; (b) evolution of anal dysplasia and the role of HPV in patients on HAART; (c) the role of gp 120 in HIV induced apoptosis of neurological cells in pathogenesis of dementia; (d) the role of GM-CSF and CD4 ligand on immunity to H. Capsulatum and HIV-1; (e) use of in vitro assays for drug interactions with protease inhibitors; and (f) the role of intestinal metabolism and bioavailability of antiretroviral drugs. The second specific aim is to expand the patient base, including women and minorities, though increased support for subunits at Wishard Hospital and Community Hospital. The work proposed in this application will be implemented through conduct of clinical trials as a member the AACTG, using an infrastructure that has been refined during 12 years as an ACTU. Specialized immunology, virology, and pharmacology laboratories will support this work.

该印第安纳州大学建议建立在以下更新应用：（1）科学和行政贡献。印第安纳州ACTU在ACTU中科学排名前20%;（2）AACTG试验的成本效益。印第安纳州在成本加权应计方面排名第三;（3）招聘妇女和少数族裔。ACTU在招聘非裔美国人方面排名第二，在女性方面排名第三。该网站的长期目标是：通过招募更多的研究人员来扩大科学和行政贡献;通过扩大Wishard医院子单位来增加妇女和少数民族的应计潜力;通过在印第安纳波利斯社区医院建立一个子单位来增加患者基础。印第安纳州大学ACTU的第一个具体目标是通过提交概念提案和AACTG协议团队和委员会的成员资格来做出科学贡献。目前，印第安纳州的调查人员在协议小组中担任32个职位。提出的概念用于：（a）依法韦仑治疗失败的补救治疗;（B）HAART患者肛门发育不良的演变和HPV的作用;（c）gp 120在痴呆发病机制中HIV诱导神经细胞凋亡中的作用;（d）GM-CSF和CD 4配体在对H.荚膜和HIV-1;（e）利用体外试验研究药物与蛋白酶抑制剂的相互作用;（f）肠道代谢的作用和抗逆转录病毒药物的生物利用度。第二个具体目标是扩大病人基础，包括妇女和少数民族，但增加对Wishard医院和社区医院的分中心的支持。本申请中提出的工作将通过作为AACTG成员进行临床试验来实施，使用作为ACTU在12年内经过完善的基础设施。专门的免疫学、病毒学和药理学实验室将支持这项工作。

项目成果

DNA fingerprinting of serial Candida albicans isolates obtained during itraconazole prophylaxis in patients with AIDS.

艾滋病患者伊曲康唑预防期间获得的系列白色念珠菌分离株的 DNA 指纹图谱。

• DOI: 10.1080/mmy.39.2.207.213
• 发表时间: 2001
• 期刊: Medical mycology
• 影响因子: 2.9
• 作者: LeMonte,AM;Goldman,M;Smedema,ML;Connolly,PA;McKinsey,DS;Cloud,GA;Kauffman,CA;Wheat,LJ;NationalInstituteofAllergyandInfectiousDiseaseMycosesStudyGroup
• 通讯作者: NationalInstituteofAllergyandInfectiousDiseaseMycosesStudyGroup

The effect of primaquine on the ultrastructural morphology of Pneumocystis carinii.

伯氨喹对卡氏肺孢子虫超微结构形态的影响。

• 发表时间: 1991
• 期刊: The Journal of protozoology
• 作者: Goheen,MP;Bartlett,MS;Queener,SF;Smith,JW
• 通讯作者: Smith,JW

Culture and filtration methods for obtaining Pneumocystis carinii trophozoites and cysts.

获得卡氏肺孢子虫滋养体和包囊的培养和过滤方法。

• 发表时间: 1991
• 期刊: The Journal of protozoology
• 作者: Durkin,MM;Shaw,MM;Bartlett,MS;Smith,JW
• 通讯作者: Smith,JW

An improved rat model to study efficacy of drugs for treatment or prophylaxis of Pneumocystis carinii pneumonia.

改进的大鼠模型，用于研究治疗或预防卡氏肺孢子虫肺炎药物的功效。

• DOI: 10.1111/j.1550-7408.1989.tb02712.x
• 发表时间: 1989
• 期刊: The Journal of protozoology
• 作者: Barlett,MS;Fishman,JA;Durkin,MM;Queener,SF;Smith,JW
• 通讯作者: Smith,JW

Incorporation of fatty acids and amino acids by cultured Pneumocystis carinii.

培养的卡氏肺囊虫掺入脂肪酸和氨基酸。

• DOI: 10.1111/j.1550-7408.1994.tb01525.x
• 发表时间: 1994
• 期刊: The Journal of eukaryotic microbiology
• 作者: Paulsrud,JR;Queener,SF
• 通讯作者: Queener,SF